scholarly journals The reduction of bone mineral density in postmenopausal women with primary hyperparathyroidism is higher in the presence of concomitant GH secretion impairment

2006 ◽  
Vol 155 (1) ◽  
pp. 41-45 ◽  
Author(s):  
Elisabetta Cecconi ◽  
Maurizio Gasperi ◽  
Maura Genovesi ◽  
Fausto Bogazzi ◽  
Lucia Grasso ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Primary Hyperparathyroidism ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Bone Remodelling ◽  
Ionized Calcium ◽  
Control Group ◽  
Mineral Density ◽  
Age At Menopause ◽  
Gh Secretion

Objective: To investigate, in a large group of postmenopausal primary hyperparathyroidism (PHP) women, whether the concomitance of GH deficiency (GHD) may contribute to the development of changes in bone mineral density (BMD). Design: GH secretion, bone status and metabolism were investigated in 50 postmenopausal women with PHP and in a control group of 60 women with no evidence of PHP, matched for age, age at menopause and body mass index (BMI). Methods: GH response to growth hormone-releasing hormone (GHRH)+arginine (Arg), femoral neck BMD (g/cm2) by dual energy X-ray absorptiometry, BMI, serum-ionized calcium, parathyroid hormone (PTH) and markers of bone remodelling were evaluated in all patients and controls. Results: Among PHP patients, GH secretion was reduced (8.8 ± 4.2 μg/l, range 1.1–16.5 μg/l) in 34 patients and normal (28.7 ± 11.8 μg/l, range 17.9–55.7 μg/l) in the remaining 16 (P < 0.05), no women in the control group had GHD (peak GH 33.8 ± 10.9 μg/l, range 21.7 ± 63.2 μg/l). Osteoporosis (T-score < − 2.5) and osteopenia (T-score > −2.5 and < −1) were found in 73.5 and 17.6% of GHD patients, in 37.5 and 43.7% of patients with normal GH secretion and 3.1 and 27% of controls. T-score and BMD were not correlated with ionized calcium, age, age at menopause, BMI, GH peak and IGF-I but were correlated with serum PTH levels in both groups. T-score was correlated with serum levels of markers of bone remodelling only in PHP patients with GHD. Conclusions: Concomitant impairment of GH secretion may play a pathogenetic role in the occurrence of changes in bone mass observed in PHP and contribute to make them more severe.

scholarly journals The relationships between bone turnover markers and bone mineral density in postmenopausal type 2 diabetic women

2016 ◽  
Vol 19 (5) ◽  
pp. 375-382
Author(s):  
Vadim V. Klimontov ◽  
Olga N. Fazullina ◽  
Alexander P. Lykov ◽  
Vladimir I. Konenkov
Keyword(s):  
Bone Mineral Density ◽  
Bone Resorption ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Bone Remodelling ◽  
Metabolic Parameters ◽  
Control Group ◽  
Mineral Density

Aim. To determine the relationships between bone remodelling markers and bone mineral density (BMD), metabolic parameters and total body composition (TBC) in postmenopausal women with type 2 diabetes (T2D).Materials and methods. The study included 140 women who were diagnosed with T2D more than five years prior. The control group included 20 postmenopausal nondiabetic women with normal BMD. The BMD and TBC parameters were assessed by dual X-ray absorptiometry. Based on their T-scores, T2D women were divided into the following groups: normal BMD (n = 50), osteopenia (n = 50) and osteoporosis (n = 40). Serum levels of bone formation markers [osteocalcin and type 1 C-terminal collagen propeptide (CICP), osteoprotegerin (an inhibitor of bone resorption), parathyroid hormone (PHT) and urinary excretion of C-terminal telopeptides of type 1 collagen (alpha-CrossLaps, or CTX-I; a bone resorption marker)] were determined by ELISA.Results. Osteocalcin levels were decreased in all groups of T2D women (all P 0.0002), without any differences between groups. Osteoprotegerin levels were reduced in all patient groups but was significantly lower in diabetic women with osteoporosis and osteopenia compared to those with normal BMD (P = 0.003 and P = 0.01, respectively). Women with osteoporosis had higher urinary CTX-I excretion than control and diabetic women with normal BMD (P = 0.01 and P = 0.01, respectively). CICP levels did not differ between groups. PHT concentrations were increased in diabetic women (P 0.0001), without any differences between groups. After multiple regression analysis, BMI, age and CTX-I excretion were all associated with lumbar BMD (R2 = 0.38, P = 0.0007), whereas age, BMI, osteoprotegerin levels and CTX-I excretion were all predictive of BMD at the proximal femur (R2 = 0.44, P = 0.00003). There was no relationship between bone remodelling markers and HbA1c, lipid metabolism or TBC.Conclusions. In postmenopausal T2D women, osteoporosis is associated with decreased serum osteoprotegerin levels and enhanced urinary CTX-I excretion. The data do not support the existence of an interrelationship between bone remodelling markers, metabolic parameters and TBC in postmenopausal women with T2D.

scholarly journals Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
A. Sánchez ◽  
L. R. Brun ◽  
H. Salerni ◽  
P. R. Costanzo ◽  
D. González ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Bone Turnover ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Bone Turnover Markers ◽  
Control Group ◽  
Bone Resorption Marker ◽  
Similar Response ◽  
Mineral Density ◽  
Turnover Markers

The aim of this study was to evaluate the effect of denosumab (Dmab) on bone mineral density (BMD) and bone turnover markers after 1 year of treatment. Additionally, the effect of Dmab in bisphosphonate-naïve patients (BP-naïve) compared to patients previously treated with bisphosphonates (BP-prior) was analyzed. This retrospective study included 425 postmenopausal women treated with Dmab for 1 year in clinical practice conditions in specialized centers from Argentina. Participants were also divided according to previous bisphosphonate treatment into BP-naïve and BP-prior. A control group of patients treated with BP not switched to Dmab matched by sex, age, and body mass index was used. Data are expressed as mean ± SEM. After 1 year of treatment with Dmab the bone formation markers total alkaline phosphatase and osteocalcin were significantly decreased (23.36% and 43.97%, resp.), as was the bone resorption marker s-CTX (69.61%). Significant increases in BMD were observed at the lumbar spine, femoral neck, and total hip without differences between BP-naïve and BP-prior. A better BMD response was found in BP-prior group compared with BP treated patients not switched to Dmab.Conclusion. Dmab treatment increased BMD and decreased bone turnover markers in the whole group, with similar response in BP-naïve and BP-prior patients. A better BMD response in BP-prior patients versus BP treated patients not switched to Dmab was observed.

scholarly journals Effects of Hormone Replacement Therapy on Bone Mineral Density in Postmenopausal Women With Primary Hyperparathyroidism

2000 ◽  
Vol 160 (14) ◽  
pp. 2161 ◽  
Author(s):  
Brandon J. Orr-Walker ◽  
Margaret C. Evans ◽  
Judy M. Clearwater ◽  
Anne Horne ◽  
Andrew B. Grey ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Hormone Replacement Therapy ◽  
Primary Hyperparathyroidism ◽  
Replacement Therapy ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Hormone Replacement ◽  
Mineral Density

scholarly journals Bone mineral density status and the need for anti-osteoporotic therapy in postmenopausal women with systemic scleroderma

2019 ◽  
pp. 72-79
Author(s):  
O. V. Dobrovolskaya ◽  
N. V. Demin ◽  
A. V. Smirnov ◽  
N. V. Toroptsova
Keyword(s):  
Bone Mineral Density ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Systemic Scleroderma ◽  
Control Group ◽  
Inflammatory Rheumatic Diseases ◽  
Mineral Density ◽  
Buffer Solution ◽  
Identification Of Persons ◽  
The One

The article is devoted to the study of bone mineral density in patients with systemic scleroderma (SSD) and the identification of persons, who needs the anti-osteoporotic treatment. A total of 170 postmenopausal women were examined: 103 patients with SSD and 67 patients without inflammatory rheumatic diseases. Osteoporosis (OP) was detected in 49.5% in the patient group and in 31% in the control group (p <0.05). The correlation relation between the bone mineral density (BMD) and body mass index was found to be direct, and the one between BMD and the duration of the disease and the cumulative dose of glucocorticoids was found to be inverse. The blood vitamin D level (25(OH)D) was significantly lower in patients than in controls (19.3 ± 7.4 ng/ml and 23.3 ± 8.6 ng/ml, respectively), and among individuals with SSD it was significantly lower in patients with OP than in patients without OP (p <0.05). 85% examined patients with SSD needed the anti-osteoporotic therapy. Treatment with the generic alendronate in the form of effervescent tablets to prepare Binosto buffer solution was effective and safe in patients with SSD with esophageal hypotension.

scholarly journals Oral Alendronate Increases Bone Mineral Density in Postmenopausal Women with Primary Hyperparathyroidism

2003 ◽  
Vol 88 (2) ◽  
pp. 581-587 ◽  
Author(s):  
C. C. Chow ◽  
W. B. Chan ◽  
June K. Y. Li ◽  
Norman N. Chan ◽  
Michael H. M. Chan ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Primary Hyperparathyroidism ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Mineral Density

scholarly journals The effect of different exercise programs on bone mineral density and physical function in women with osteoporosis: A randomized controlled trial

2017 ◽  
Vol 1 (1) ◽  
pp. 47
Author(s):  
Lumnije Hoxha Kamberi
Keyword(s):  
Bone Mineral Density ◽  
Muscle Strength ◽  
Physical Function ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Controlled Trial ◽  
Intervention Group ◽  
Control Group ◽  
Mineral Density ◽  
Significant Difference

Aim: Osteoporosis is a multifactorial progressive skeletal disorder characterized by reduced bone mass. Exercise is widely recommended to reduce osteoporosis, falls and related fragility fractures. The purpose of this study was to investigate the effects of land exercise (LE) and aquatic exercise (AE) on physical function and bone mineral density (BMD). Methods: Fifty-eight postmenopausal women, aged 50-70 years,  diagnosed with osteoporosis according to BMD measures, enrolled in this study. The subjects were randomly assigned to either the intervention group (LE group) or the control group (AE group). Physical function and BMD were assessed in all subjects in both groups before and after 10 months of intervention. The muscle strength,   flexibility, balance, gait time and pain were measured to assess physical function. Bone mineral density at the lumbar spine was measured by dual energy X-ray absorptiometry (DEXA). Results: There were no significant differences between the two groups in the baseline anthropometric data. The two groups were similar with respect to age, weight, height, and body mass index (p>0.05). After the exercise program, muscle strength, flexibility, gait time, pain, and bone density (p<0.001)  significantly improved with LE compared to AE. There was no significant difference between the two groups in balance at the 10-month follow-up. Conclusion: Significant improvements in physical function and BMD suggest that LE is a possible alternative for     postmenopausal women with OP. Clinical rehabilitation impact: In the current  available literature there is insufficient data regarding combined regimens,       additionally, conclusions from our research can inspire further studies in order to promote land and water based exercise.

Sign in / Sign up

Export Citation Format

Share Document